SCHEDULE: Vanguard Group Reports Zero Beta Bionics Stake

The Vanguard Group has reported zero beneficial ownership in Beta Bionics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Beta Bionics Inc. Common Stock.
• As of March 13, 2026, The Vanguard Group reports 0 shares beneficially owned, representing 0% of the Common Stock class.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions will now report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated entities.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Beta Bionics Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Beta Bionics Inc. as it primarily reflects an internal organizational change within The Vanguard Group rather than a direct positive or negative assessment of Beta Bionics' prospects.

Positives

• The filing provides clear transparency regarding The Vanguard Group's current beneficial ownership status as a parent entity.
• The internal realignment and disaggregated reporting may lead to more granular insights into specific fund holdings by Vanguard's subsidiaries in the future.

Negatives

• The Vanguard Group, as the parent entity, no longer directly reports beneficial ownership of Beta Bionics Inc. shares, indicating a complete divestment from their consolidated reporting perspective.

Future Outlook

The filing indicates a shift in The Vanguard Group's reporting structure for beneficial ownership, with future filings for Beta Bionics Inc. potentially coming from its subsidiaries or business divisions rather than the parent entity.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that institutional investors like The Vanguard Group frequently adjust their internal reporting structures and portfolio allocations. This specific filing reflects an internal organizational change rather than a direct investment thesis change regarding Beta Bionics Inc. The disaggregated reporting aligns with broader trends towards increased transparency in institutional holdings, albeit at a subsidiary level.

Stakeholder Impact

• Shareholders: May observe a change in reported institutional ownership data for Beta Bionics Inc. from The Vanguard Group, though underlying holdings by Vanguard's funds may still exist under different reporting entities.
• Investment Professionals: Will need to track beneficial ownership from Vanguard's disaggregated entities for a complete picture of their holdings.

Next Steps

• Future beneficial ownership filings related to Beta Bionics Inc. may be reported by Vanguard's disaggregated subsidiaries or business divisions.

Key Dates

Keywords

Beta Bionics Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Institutional Ownership